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Introduction:
Oculopharyngeal muscular dystrophy (OPMD) is a disorder characterized by the
onset of progressive ocular ptosis, dysphagia, and proximal muscle weakness during
middle age. The cause of this disorder is an autosomal dominant gene mutation that
consists of a stable trinucleotide repeat in PABPN1 on chromosome 14. The
trinucleotide repeat ranges from (GCG)8-13 with some mutations also containing GCA.1
Thus far only (GCG)9 has been seen in Hispanic New Mexican families.2 Although this
disease does not appear to shorten lifespan, it clearly diminishes quality of life. It is
potentially amenable to treatment, as demonstrated in a recent mouse model treated with
doxycycline in which typical intranuclear inclusions were decreased and muscle strength
and function increased.3 As such, it has become important to devise noninvasive
measures of muscle function in order to evaluate potential treatment effects. A single
prior P-31 Magnetic Resonance Spectroscopy study of forearm muscle has been
conducted in patients with OPMD.4
Myotonic muscular dystrophy type I (DM1), an autosomal dominant disorder
with uneven penetrance, is the most common muscular dystrophy of adults with an
estimated lifetime incidence of approximately 1 in 8000.5 This disease is due to an
unstable trinucleotide (CTG) repeat located in the 3’ untranslated region of the DMPK
(dystrophica myotonica protein kinase) gene on chromosome 19q13.3.6,7,8 Normal
individuals have DMPK alleles with between 5 and 35 (CTG)n repeats that are stably
transmitted, while diseased individuals have alleles containing 50 to several thousand
(CTG)n repeats that are no longer stable.6,9,10 The disease shows a tendency to have an
earlier onset in subsequent generations, a phenomenon known as anticipation, which is
accompanied by expansions in the size of the CTGn repeat region. An inverse correlation
between CTGn repeat size and age of onset has been noted, as well as a fairly broad
correlation between repeat size and the severity of the disease.9,11 These correlations are
quite variable and thus, specific ranges of repeat size cannot be used to predict age of
onset or disease severity in individual patients. The majority of persons with DM1
present in adulthood with distal muscle weakness and wasting accompanied by myotonia,
a sustained muscle contraction, caused by abnormal activity of the sarcolemma.12,13,14
DM1 has multisystemic effects that include endocrinopathy, cardiac conduction
abnormalities, neurocognitive changes, and the development of cataracts, in addition to
the aforementioned effects on skeletal muscle. A treatment trial for weakness in DM1
looked at the efficacy of creatine monohydrate supplementation in DM1 patients, with
the finding that there was no benefit.15 Researchers in this trial used 31P MRS imaging
of the forearm muscles to help measure the response to the treatment. This highlights the

usefulness of the noninvasive technique of 31P MRS imaging in studying muscular
dystrophies and the response of muscle to treatments.
Magnetic resonance imaging can be used to evaluate muscle size, signal
characteristics and to distinguish the pattern and degree of atrophy. 31P MRS has been
used in the investigation of muscle energy metabolism in health and disease for over 20
years.16 By measuring unbound phosphorus metabolites with this technique, muscle
energy metabolism can be investigated in a noninvasive and painless fashion during rest,
exercise, and recovery from exercise for serial monitoring of oxidative and glycolytic
metabolism of muscle. It is possible to measure unbound phosphorus metabolites in
living human muscle with concentrations of at least 1 mM. Phosphorus spectra from
muscle contain five major peaks related to energy metabolism: three from adenosine
triphosphate (ATP), one from phosphocreatine (PCr) and one from inorganic phosphates
(Pi). Two additional peaks arise from phosphomonoesters (PME) and (PDE).17
The aim of this study was to further characterize the bioenergetics of muscle in
patients with OPMD and DM1. To date there has not been a good noninvasive way to
follow the course of muscle in OPMD and DM1 other than with clinical manifestations
such as muscle weakness. 31P MRS is a promising technology to evaluate disease course
over time or to determine response to treatment. The response of muscle to exercise in
these and other muscular dystrophies also remain unclear, with some types of exercise
showing benefit and others detriment depending on the specific disease. 18 More
knowledge about the bioenergetics of muscle in OPMD and DM1 could help clinicians
determine whether exercise is beneficial or detrimental. Thus far, there have been no
studies reporting 31P MRS in the gastrocnemius muscle of OPMD, and only two in DM1.

Materials and Methods:
Subjects:
A total of 34 subjects (12 OPMD, 11 DM1, 11 controls) were recruited to
participate in this study. Preexisting clinical databases of patients with previously
diagnosed OPMD and DM1 were used to identify potential subjects. The recruited
subjects had no contraindications to magnetic resonance testing. An effort was made to
age and sex-match the participants in each group; however with the limited numbers of
patients available this was not entirely possible. See table 1 for age and gender
distribution. This study was approved by the University of New Mexico Human
Research Review Committee, and informed verbal and written consent was obtained
from each participant.
Scans were performed and data obtained from all patients in the OPMD and
control groups. Data from three patients in the DM1 group was not usable. One male
patient with DM1 was unable to complete the study due to the presence of a leg brace
that interfered with proper functioning of the exercise apparatus. The data for the second
DM1 male was unusable, due to poor quality spectra with peaks indistinguishable from
noise. This participant was noted to have extensive muscle wasting, and was unable to
return for a repeat scan due to his declining health status. The data for the third DM1
female patient was not obtained according to protocol with incorrect resting and exercise
duration. This participant did not respond to messages requesting that she return for a
repeat scan.
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P MRS methodology:
Experiments were performed on the 4 Tesla MRI scanner at the Mind Imaging Center
(Bruker Biospin , Billerica MA). Subjects lay supine in the bore of the magnet with a
dual tuned proton/phosphorus (1H/31P) transmit/receive coil secured around the lower
right leg at the level of the gastrocnemius and the foot was secured into the exercise
apparatus. The location of the gastrocnemius within the magnet was confirmed by T1
weighted 1H localizing images obtained in the axial plane. An anatomical scan to allow
the placement of the chemical shift imaging slab was then acquired using a 3D T1
weighted gradient refocused echo sequence (fov = 200 x 200 mm, matrix = 256 x 256, 96
slices, with a 1 mm slice thickness giving a final resolution of 0.8 mm x 0.8 mm x 1.0
mm.). Shimming on the proton signal from tissue water optimizes magnetic field
homogeneity. Chemical shift imaging (CSI) 31P MRS data were then acquired at 60 MHz
from a 40mm thick axial slice, which includes the gastrocnemius muscle. The sensitive
volume of the coil limits the volume of the tissue sampled in the anterior posterior
direction in the leg. A custom developed exercise apparatus that allows for 31P MRS data
acquisition during exercise in the magnetic resonance image (MRI) scanner was used.
This apparatus has been used previously in a study on sarcopenia by Waters et. al.19 The
exercise apparatus is a rigid frame with a wheel that turns around its axis by pushing
down on a pedal with the foot. A static line connects the outer radius on one side of the
wheel, over a pulley to a hook suspending calibrated weights from a frame. The weight to
be lifted was chosen for each subject based on subject assessment of effort and ability to
finish the six minutes of exercise. Contraction of the gastrocnemius allows for a 9 cm
vertical displacement of the weights.
CSI data from an 8x8 matrix (fov = 200 X 200) are sampled using a spectral width of
3000 Hz, and a recycle time (TR) of 1 second. This will produce one CSI data set in
approximately one minute (64 sec). Subjects were asked to rest for the first four CSI
acquisitions, then to contract the calf to raise the weights at the rate of 60 repetitions per
minute, for six CSI acquisitions, then the subjects were told to rest again, allowing
muscle recovery for six CSI acquisitions. The contraction rate of 60 repetitions per
minute was standardized and maintained by having the subject control the contraction
frequency using the audible gradient noise of the scanner acquisition set at a 1 second
recycle time.
Quantification of mitochondrial function:
Data was analyzed using jMRUI software (jMRUI v. 2.2, European Community) in the
time domain. The 1H localizing image that was taken for alignment of the leg was used to
pick voxels that were completely with in the gastrocnemius muscle. The data for these
voxels was then viewed by two blinded evaluators (LM and LF) and the voxel with the
best signal to noise ratio was used for the analysis. For visualization, each free induction
decay (FID) was processed with a 5 Hz exponential line broadening before zero filling
and Fourier transformation. All spectra were manually phased using zero and first-order
phase corrections. Resonance peak areas for PCr, Pi and ATP were measured by line
fitting of the spectrum. Signal-to-noise ratios were sufficient to allow PCr, and Pi to be
quantified with a temporal resolution of 1 minute during exercise and recovery. Baseline
(rest) cytosolic [PCr] and [Pi] were calculated from the signal intensity ratios PCr/βATP
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and Pi/βATP respectively, taking ATP at rest to be 8.2 mmol/L cell water as follows:
[PCr] = (PCr/βATP) 8.2 mmol/L.20,21 Metabolite peak areas were normalized to 100%
by using the average metabolite value obtained during the four-minute rest (pre-exercise)
as a reference. Concentrations are expressed as the percent change from baseline levels
defined as 100%. Thus, PCr and Pi, indicate peak areas obtained from spectra and [PCr]
and [Pi] are calculated concentrations. Cytosolic [ADP] is calculated as follows: [ADP] =
({[TCr]/[PCr]-1}[ATP]/(K/[H+]) where [TCr] = total creatine = 42.5 mmol/L cell water,
and K is the equilibrium constant of creatine phosphokinase (1.66 x 109L/mol).20,21
Relative changes of PCr, Pi, and [ADP] are expressed graphically as percentages of the
resting average.
Statistical Analysis:
Data from patients was subdivided into those with DM1, those with OPMD, and control
subjects. The overall analysis of the time course of each metabolite, (PCr, Pi, and ADP)
was done by repeated measures ANOVA with time as the repeated factor and the three
patient groups (DM1, OPMD, control) as the grouping factor. Post hoc testing was done
by unpaired t-tests at each time point. The variables are reported as mean + SE. A value
of P<0.05 was considered statistically significant.

Results:
Demographics (Table 1)
Table 1
Group
OPMD
(n=12)
DM1 (n=11)
Control
(n=11)

Age (years)

Gender (% female)

53.2 + 8.9
43.9 + 9.4

67% (8)
73% (8)

44.6 + 10.7

64% (7)
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P MRS baseline concentrations (Table 2)
During the baseline resting period the values for [PCr] were significantly
decreased in the DM1 group versus controls, and the OPMD group also showed this trend
however it was not statistically significant. The baseline resting [ADP] level was
significantly higher in the DM1 group than in controls.
Table 2
OPMD
DM1
Control

[PCr] (mM)
0.472
0.4579
0.4958

SE
0.0112
0.01
0.0063

P value
0.0792
0.0065

OPMD
DM1
Control

Pi (Mm)
0.0548
0.0601
0.0521

SE
0.0032
0.003
0.0023

P value
0.5057
0.0508

[ADP] (µM)

SE

P value

OPMD
DM1
Control

5.7018
6.6995
5.1897

0.4279
0.4422
0.2702

0.3239
0.0116

Data reported as mean and standard error (SE). P values are for diseased group compared
with controls.
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P MRS relative metabolite change normalized to resting baseline during rest, exercise
and recovery (Figures 1, 2, and 3).
The minimum [PCr] was significantly lower in OPMD patients than in controls
(Fig. 1) after the first minute of exercise (step 5) and at the end of exercise (steps 9 & 10).
The differences seen for the DM1 patients versus controls were not statistically
significant.
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Figure 1
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Step refers to each 64 second period of data acquisition. Steps 1-4 are during the rest
period, Steps 5-10 are during exercise, and steps 11-16 are during recovery.
The maximum [Pi] was significantly higher in OPMD patients than in controls
(Fig. 2) after the first minute of exercise (step 5) and at the end of exercise (steps 9 & 10).
The differences seen for the DM1 patients versus controls were not statistically
significant.
Figure 2
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The maximum [ADP] was significantly higher in OPMD patients than in controls
(Fig. 3) throughout the exercise period (steps 5,6,7, 9 & 10). The differences seen for the
DM1 patients versus controls were not statistically significant.
Figure 3
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Discussion
The goal of this study was to characterize the bioenergetics of muscle by P-31
MRS at rest, with exercise and in recovery in patients with OPMD and DM1. This is
especially important for the patients with OPMD because of the scarcity of studies
involving this disease. The only P-31 MRS study in patients with OPMD that was
uncovered during our literature search was a small study by Zochodne et al that involved
5 siblings with OPMD.4 The investigators in this study looked at the forearm flexor
muscles during rest, exercise, and recovery periods with the findings that the OPMD
patients had reduced PCr/(PCr +Pi) ratios and increased pH in resting muscle compared
to normal controls. During exercise they observed an early and prominent fall in
PCr/(PCr +Pi) as well as an excessive intracellular muscle acidosis that was slow to
recover after exercise had ceased. All of these findings reached statistical significance
and are of particular interest since OPMD generally affects proximal limb muscles, but
these abnormalities were noted in the more distal muscles of the forearm.
Our study looked at the gastrocnemius muscle which is also a distal muscle that is
not severely affected in OPMD patients. We found larger decreases in [PCr] in the
OPMD group compared to controls early during exercise and at the end of the exercise
period, which is similar to the results obtained in the study by Zochodne et al . A trend
toward decreased [PCr] during rest was noted in our study, however this did not reach
statistical significance. The [ADP] was found to increase to higher levels during exercise
compared with controls. These findings indicate that even though the gastrocnemius
muscle is not clinically affected in OPMD patients, there is 31-P MRS evidence of
altered function. This lends further evidence to OPMD being a widespread disorder of
striated muscle, even when muscle strength is clinically judged as normal.
One possible mechanism for the results that we obtained is that within the muscle
there is a reduced number of functioning muscle fibers. The results that we obtained of
an early and excessive fall in [PCr] and an elevated [ADP] during exercise could indicate
that there is an increase in ATP hydrolysis used for cross-bridge movement in the
depleted pool of muscle fibers. This leads to increased ADP, which then undergoes
phosphorylation by PCr back into ATP in a reaction catalyzed by creatine kinase. The
excessive fall in [PCr] compared to controls is attributed to a greater demand placed on
each remaining functional muscle fiber. Another possible mechanism is that there is a
normal amount of muscle fibers but they are not functioning normally. At moderate
levels of exercise, such as in our study, most of the energy used for muscle contraction is
generated by oxidative phosphorylation with glycogen being the major fuel for the first
several minutes after exercise begins. The dystrophic process could affect one of the
steps in oxidative phosphorylation thus slowing this process. This would lead to
increased PCr depletion and elevated end-exercise [ADP].21
Our results obtained from the patients with DM1 showed similar trends to the
results from the OPMD group; however most of the findings in the DM1 group did not
reach statistical significance. We had a small number of patients in each group to begin
with and unfortunately data from three of the DM1 participants was unusable for the
reasons described previously under the heading Subjects. The smaller number of
participants decreased the statistical power of our study to distinguish differences
between the DM1 group and the control group. A decreased resting [PCr] and an
elevated resting [ADP] compared to controls were found to be significant in our study.
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These results can be compared with those by Barany et al, and Barnes et al, who have
previously performed 31P MRS studies in patients with DM1 on the gastrocnemius
muscle.14,23 Barany et al studied 4 patients with DM1 as part of a larger study on leg
neuromuscular diseases, with the finding that DM1 patients had elevated ATP/PCr ratios
compared to controls. Barnes et al studied 14 patients with myotonic dystrophy, however
only 7 patients were able to exercise for 5 minutes. In these patients an elevated resting
intracellular pH was noted, as well as elevated [ADP] levels, and a reduced
phosphorylation potential. These findings were even more pronounced in the patients
that could not complete the exercise regimen. During exercise in the DM1 patients
phosphocreatine was depleted more rapidly, ADP concentrations were higher, and
calculated ATP turnover was elevated compared to controls. Our results during exercise,
though not statistically significant, show trends towards elevated [ADP] and decreased
phosphorylation potential. This would be consistent with the study by Barnes et al with
these findings thought to be due to both reduced mitochondrial and glycogenolytic
function.14
In conclusion we have been able to demonstrate bioenergetic abnormalities in the
gastrocnemius muscle during exercise in patients with OPMD. Unfortunately the
differences from controls in patients with myotonic dystrophy did not reach statistical
significance, likely due to unusable data from several participants and thus decreased
statistical power. The findings in the OPMD patients provide promise that 31-P MRS
could be used to noninvasively monitor bioenergetic indices that could be followed
serially during therapeutic trials. The hope is that improvement in these bioenergetic
indices for both OPMD and DM-1 patients might precede or accompany an improvement
in clinical measures.
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